{
  "id": 12745599,
  "title": "Director Hershberg sells $125k in Recursion Pharmaceuticals stock",
  "url": "https://urgent.news/2026/10/08/director-hershberg-sells-125k-in-recursion-pharmaceuticals-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T00:01:40.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/director-hershberg-sells-125k-in-recursion-pharmaceuticals-stock-93CH-4937745"
  },
  "original_language": "en",
  "account": "Director Robert Hershberg of Recursion Pharmaceuticals sold 25,000 shares of the company's Class A Common Stock on October 6, 2026. The sale amounted to $125,000, with each share priced at $5.00. At present, the stock trades at $4.27, marking a decline from the sale price. However, shares have seen a 26% gain over the past six months.\n\nNotably, this sale came after Hershberg acquired 25,000 Class A Common Stock shares on the same day, purchasing them at $2.22 per share, totaling $55,500. This acquisition was made in accordance with a Rule 10b5-1 trading plan Hershberg established on December 17, 2025.\n\nIn addition to the share sale, Hershberg exercised stock options to purchase another 25,000 shares of Class A Common Stock at an exercise price of $2.22 per share. The shares were granted over time, with one forty-eighth (1/48th) of the shares becoming vested each month starting one month after March 16, 2020.\n\nFollowing these transactions, Hershberg now directly owns 162,156 shares of Recursion Pharmaceuticals' Class A Common Stock, along with 500,000 stock options. Despite ongoing profitability challenges, the company maintains a Fair financial health rating. Recursion Pharmaceuticals reported its financial results for the second quarter of 2026, revealing a revenue shortfall of $4.48 million, falling short of analysts' expectations. The company also announced a loss of $0.25 per share, exceeding the anticipated loss of $0.24 per share. In response, Recursion revised its full-year cash operating expense guidance to $375 million. The company's cash balance of approximately $557 million is projected to sustain operations through early 2028. These developments follow a challenging period for Recursion, with shares dropping by 7.9% to $3.05 in premarket trading.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Recursion Pharmaceuticals director Blake Borgeson sells $242,000 in stock",
        "url": "https://urgent.news/2026/10/08/recursion-pharmaceuticals-director-blake-borgeson-sells-242-000-in",
        "published": "2026-10-08T00:16:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}